Publication | Closed Access
Time- and dose-dependent changes in ejection fraction determined by radionuclide angiography after anthracycline therapy.
40
Citations
0
References
1978
Year
Heart FailurePharmacotherapyCardiovascular ToxicityDiastolic FunctionOncologyRadionuclide Ejection FractionRadionuclide AngiographyRadiopharmaceutical TherapyRadiation OncologyCardiologyNuclear MedicineEjection FractionRadiologyAnthracycline TherapyHealth SciencesRadiation TherapyMedical ImagingPharmacologyRadionuclide EfrnCardiovascular DiseaseMedicineAcute ToxicityAnesthesiology
Twenty patients receiving anthracycline chemotherapy were studied by the technique of radionuclide ejection fraction (EFrn). This technique is capable of detecting noninvasively small changes in left ventricular function. Two patterns of anthracycline toxicity emerged: (a) an acute toxicity observable between 24 and 72 hours after administration of greater than 60 mg/m2 of anthracycline with some recovery noted by 72-96 hours (no changes were observed within the first 4 hours after administration of the drug), and (b) a chronic dose-dependent decrease in left ventricular function when studies were performed 3 weeks after the last dose of anthracycline. After anthracyclines were stopped, four of four patients showed significant recovery in left ventricular function. We concluded that the radionuclide EFrn is a sensitive noninvasive index of left ventricular function which can be used to serially study patients receiving anthracycline therapy and can potentially be used to evaluate pharmacologic means for preventing anthracycline cardiotoxicity.